TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24187859

Group type: EXPERIMENTAL
Intervention: Low-dose Huadananshen mistura (10 mL/day)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: High-dose Huadananshen mistura (20 mL/day)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 244
Study: 21192290

Group type: EXPERIMENTAL
Intervention: Psychosocial distress measured with the Symptom Checklist-90-Revised (SCL-90-R)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Psychosocial distress measured with the SCL-90-R
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: SCL-90 and pain intensity as predictors of RMDQ
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: All baseline characteristics analyzed in relation to RMDQ
Number of subjects: 293
Study: 19647940

Group type: EXPERIMENTAL
Intervention: Intra-annular PIRFT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study: 17283313

Group type: EXPERIMENTAL
Intervention: ApoE-epsilon4 carriers with long duration of epilepsy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ApoE-epsilon4 carriers
Number of subjects: 87

Group type: COMPARATOR
Intervention: non-epsilon4 carriers
Number of subjects: 87
Study: 15531677

Group type: EXPERIMENTAL
Intervention: Triple-fortified salt (TFS) with 30 mug I, 2 mg Fe, and 60 mug vitamin A/g salt
Number of subjects: 157

Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 157
Study: 11514766

Group type: EXPERIMENTAL
Intervention: Mini-invasive static nail (experimental device with a locked intramedullary nail and two nonparallel seven-millimeter cervicocephalic screws)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dynamic hip screw (sliding screw plate)
Number of subjects: 60
Study: 9779766

Group type: EXPERIMENTAL
Intervention: DTPa-IPV (Group 1)
Number of subjects: 115

Group type: COMPARATOR
Intervention: DT-IPV (Group 2)
Number of subjects: 115
Study: 7930242

Group type: EXPERIMENTAL
Intervention: Abbreviated heparin therapy (n = 118)
Number of subjects: 238

Group type: COMPARATOR
Intervention: 24-hour heparin therapy (n = 120)
Number of subjects: 238
Study: 3066803

Group type: EXPERIMENTAL
Intervention: Experimental interventions based on self‐efficacy and family stress theory during hospitalization and for 3 months thereafter
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 31609869

Group type: EXPERIMENTAL
Intervention: Chair yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chair-based exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 29211741

Group type: COMPARATOR
Intervention: Acupuncture sessions (up to twelve sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alexander Technique lessons (up to twenty lessons)
Number of subjects: 0
Study: 26293196

Group type: EXPERIMENTAL
Intervention: Preintervention preparation (reading a training manual and demonstration on a teddy bear)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no preintervention preparation)
Number of subjects: 60
Study: 24188638

Group type: EXPERIMENTAL
Intervention: Community-based distribution program by SWAP
Number of subjects: 0
Study: 22110268

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation with Peg-IFN-α 2b plus ribavirin
Number of subjects: 69
Study: 19396424

Group type: EXPERIMENTAL
Intervention: Sensor-guided pump management
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (standard insulin pump regimen)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sensor-guided pump management (within intervention group)
Number of subjects: 62
Study: 16793944

Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol (or-EE) 100 microg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Testosterone 250 mg twice a week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA) 100 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol (td-E) 100 microg twice a week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Estradiol (both routes)
Number of subjects: 50
Study: 14666945

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU per kg vitamin E plus placebo)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g per day vitamin C plus placebo)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (placebo plus placebo)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vitamin C and E (1 g per day vitamin C plus 200 IU per kg vitamin E)
Number of subjects: 7
Study: 10736906

Group type: EXPERIMENTAL
Intervention: Nurse intervention (two appointments with an epilepsy nurse)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 251
Study: 8557013

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.45 mg kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atracurium (0.35 mg kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium (0.075 mg kg‐1)
Number of subjects: 0
Study: 1718756

Group type: EXPERIMENTAL
Intervention: H/H (7.5% NaCl and 6% dextran 60)
Number of subjects: 49

Group type: COMPARATOR
Intervention: RL (Ringer's lactate)
Number of subjects: 49
Study: 6752961

Group type: EXPERIMENTAL
Intervention: ONO 802 vaginal suppository (1.0 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 125
Study: 31513027

Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Tunnel Dissection (ESTD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic Submucosal Dissection (ESD)
Number of subjects: 40
Study: 31210499

Group type: EXPERIMENTAL
Intervention: Polarity therapy (4 sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (information on healthy sleep habits)
Number of subjects: 47
Study: 30445943

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 180
Study: 26852833

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (two 50‐mg tablets) and 2% lidocaine gel (3 mL applied on anterior cervical lip and cotton swab soaked in 2% lidocaine gel in cervical canal)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (tablets and gel)
Number of subjects: 90
Study: 24172842

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) over 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Time-matched social contact (SC)
Number of subjects: 61
Study: 22330307

Group type: EXPERIMENTAL
Intervention: SAR 1118 (0.1%, 1.0%, 5.0%)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 20236255

Group type: EXPERIMENTAL
Intervention: Plasma lactate dehydrogenase (LDH) measured within 12 h post partum
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measured within 12 h post partum
Number of subjects: 205

Group type: COMPARATOR
Intervention: Randomized group for calculation of predictive value of enzymes for detection of HIE
Number of subjects: 205
Study: 18519582

Group type: EXPERIMENTAL
Intervention: Training-only group (5 hr of group speech perception training)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Training plus psychosocial group (5 hr of group speech perception training and psychosocial exercises)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 16
Study: 16000278

Group type: EXPERIMENTAL
Intervention: PFR (Peak Filling Rate)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TTPF (Time to Peak Filling)
Number of subjects: 90
Study: 12440496

Group type: EXPERIMENTAL
Intervention: CMW-1 bone cement with gentamicin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Palacos bone cement with gentamicin
Number of subjects: 51
Study: 10609971

Group type: EXPERIMENTAL
Intervention: 15‐mg nicotine patch plus behavioral treatment
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo patch plus behavioral treatment
Number of subjects: 410
Study: 7547655

Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine (5 micrograms/mL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine-epinephrine and bupivacaine 0.5%)
Number of subjects: 38
Study: 1683191

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hydroxyzine hydrochloride (25 mg t.i.d.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg t.i.d.)
Number of subjects: 36
Study: 7185513

Group type: EXPERIMENTAL
Intervention: Ethambutol hydrochloride tablets (15 mg/kg dosage)
Number of subjects: 11
Study: 30900297

Group type: EXPERIMENTAL
Intervention: Rectal fluid administration (plain water)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous fluid administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nasogastric fluid administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no treatment, water and feed withheld)
Number of subjects: 6
Study: 27518488

Group type: EXPERIMENTAL
Intervention: Flurbiprofen Axetil (1.0 mg/kg) before anesthesia induction (Group F1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo before anesthesia induction (Group C)
Number of subjects: 90
Study: 26462811

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 164) participated in a 6-week course designed to improve subjective wellbeing (SWB)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 252
Study: 24592974

Group type: EXPERIMENTAL
Intervention: Subliminal prime (word 'death' presented outside of awareness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supraliminal prime (participants answered questions about death)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double death prime (combination of subliminal and supraliminal primes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no priming)
Number of subjects: 0
Study: 22521201

Group type: EXPERIMENTAL
Intervention: Customized twice‐daily text messages
Number of subjects: 40

Group type: COMPARATOR
Intervention: No text messages (Control)
Number of subjects: 40
Study: 20128935

Group type: EXPERIMENTAL
Intervention: Regulatory match
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mismatch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline control group
Number of subjects: 0
Study: 17568244

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Routine post-discharge care
Number of subjects: 288
Study: 15692469

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% (twice daily at first signs or symptoms until clearance for 2 years)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% (used only in the second year)
Number of subjects: 91
Study: 12373693

Group type: EXPERIMENTAL
Intervention: Epidural block (EDA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: General anesthesia alone (control)
Number of subjects: 14
Study: 10022424

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (estradiol valerate, 2 mg daily; n = 7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 12
Study: 1424269

Group type: EXPERIMENTAL
Intervention: Topical application of 13‐cis‐retinoic acid (0.1% cream)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle only (placebo)
Number of subjects: 9
Study: 3933601

Group type: EXPERIMENTAL
Intervention: L-5HTP
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 43
Study: 31330811

Group type: EXPERIMENTAL
Intervention: Best magnesium formulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Worst magnesium formulation
Number of subjects: 30
Study: 28111929

Group type: EXPERIMENTAL
Intervention: CDFR0209 (omeprazole 40 mg + sodium bicarbonate 1100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed-release omeprazole (omeprazole-DR, Losec 40 mg)
Number of subjects: 30
Study: 26753527

Group type: EXPERIMENTAL
Intervention: CIdef (corneal illumination function set to default level of 50)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CIlow (corneal illumination function set to low 5)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison between CIdef and CIlow at 1.0 fc
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison between CIdef and CIlow at 0.0 fc
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intra-/inter-grader variability
Number of subjects: 25
Study: 26116309

Group type: EXPERIMENTAL
Intervention: IMF-screws (IMFS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Arch bars
Number of subjects: 50
Study: 23986962

Group type: EXPERIMENTAL
Intervention: Alcohol-free EO mouthrinse (LISTERINE Zero)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Alcohol-free CPC-containing mouthrinse (Colgate Plax)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Negative control (5% flavored, colored hydroalcohol)
Number of subjects: 337
Study: 21458845

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/d
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 18289655

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) of varying doses (frequency, intensity, duration)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity Physical Activity (PA)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lower-intensity Physical Activity (PA)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Leisure-time Physical Activity (PA)
Number of subjects: 67
Study: 17146066

Group type: EXPERIMENTAL
Intervention: Interval exercise
Number of subjects: 98

Group type: COMPARATOR
Intervention: High-intensity continuous exercise
Number of subjects: 98
Study: 12559514

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10892694

Group type: EXPERIMENTAL
Intervention: Pulsatile hypertonic saline nasal irrigation using a Water Pik device, twice daily for 3 to 6 weeks.
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Pulsatile hypertonic saline nasal irrigation
Number of subjects: 211
Study: 9534937

Group type: EXPERIMENTAL
Intervention: LOW plasma volume expansion (14% using 6% dextran solution)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HIGH plasma volume expansion (21% using 6% dextran solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LOW and HIGH plasma volume expansion
Number of subjects: 8
Study: 7961010

Group type: EXPERIMENTAL
Intervention: Concurrent cis-platinum and radiation (20 mg/m2 continuous infusion over 24 hours on days 1-4 and 22-25 of radiation schedule)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Concurrent cis-platinum and radiation
Number of subjects: 101
Study: 2884889

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 16
Study: 31960896

Group type: EXPERIMENTAL
Intervention: Volux injectable gel
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (3 months later)
Number of subjects: 132
Study: 29092012

Group type: EXPERIMENTAL
Intervention: NEPA (netupitant 300 mg and palonosetron 0.50 mg)
Number of subjects: 828

Group type: COMPARATOR
Intervention: APR/GRAN (aprepitant and granisetron)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: NEPA
Number of subjects: 828

Group type: COMPARATOR
Intervention: APR/GRAN
Number of subjects: 828
Study: 27404053

Group type: EXPERIMENTAL
Intervention: MPFF 1000 mg
Number of subjects: 162

Group type: COMPARATOR
Intervention: MPFF 500 mg
Number of subjects: 162
Study: 25355261

Group type: EXPERIMENTAL
Intervention: Yoga intervention for 4 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 100
Study: 24622491

Group type: EXPERIMENTAL
Intervention: SmokeRx program (herbal regimen)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 42
Study: 20154259

Group type: EXPERIMENTAL
Intervention: Tilt table inclinations from 15 to 90 degrees in steps of 15 degrees
Number of subjects: 15
Study: 18211742

Group type: COMPARATOR
Intervention: Emotion-based prevention program (EBP) in rural community
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotion-based prevention program (EBP) in inner city
Number of subjects: 0
Study: 16052316

Group type: EXPERIMENTAL
Intervention: Ondansetron plus metopimazine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ondansetron monotherapy
Number of subjects: 12
Study: 14712884

Group type: EXPERIMENTAL
Intervention: Formoterol 9 pmicro b.i.d.
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 pmicro b.i.d.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 10642806

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day divided into three doses
Number of subjects: 41

Group type: COMPARATOR
Intervention: Increased systemic immunosuppression (IS) only
Number of subjects: 41
Study: 9032894

Group type: EXPERIMENTAL
Intervention: 0.1 ml (2 micrograms) of recombinant hepatitis B vaccine
Number of subjects: 122

Group type: COMPARATOR
Intervention: 1.0 ml (20 micrograms) of recombinant hepatitis B vaccine
Number of subjects: 122
Study: 1296148

Group type: EXPERIMENTAL
Intervention: carbocalcitonin i.m. 40 UMRC/day/1 month and 40 UMRC/alternating days/2 months followed by 1 month of wash-out for 11 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: carbocalcitonin nasal spray 80 UMRC/day/1 month and 80 UMRC/alternating days/2 months followed by 1 month of wash-out for 11 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ipriflavone x os 600 mg/day/3 months followed by 1 month of wash-out for 3 times
Number of subjects: 90
Study: 6378309

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (TV)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Selective vagotomy and drainage (SV)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 233
Study: 31529491

Group type: EXPERIMENTAL
Intervention: 2012 survey
Number of subjects: 111168

Group type: COMPARATOR
Intervention: 2005 survey
Number of subjects: 111168
Study: 30083842

Group type: EXPERIMENTAL
Intervention: M-TURP
Number of subjects: 246

Group type: COMPARATOR
Intervention: B-TURP
Number of subjects: 246
Study: 26654691

Group type: EXPERIMENTAL
Intervention: Universal Screening (Phase 2)
Number of subjects: 236791

Group type: EXPERIMENTAL
Intervention: Universal Screening + Intervention (Phase 3)
Number of subjects: 236791

Group type: COMPARATOR
Intervention: Treatment as Usual (Phase 1)
Number of subjects: 236791
Study: 24611967

Group type: EXPERIMENTAL
Intervention: Metformin (250 mg t.i.d.) and carnitine-orotate complex (300 mg t.i.d.)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Metformin (250 mg t.i.d.)
Number of subjects: 52
Study: 22065377

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty for osteoporosis
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty for metastases
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty for myeloma
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty for all groups
Number of subjects: 466
Study: 20001318

Group type: EXPERIMENTAL
Intervention: Active LLLT with nimesulide 200 mg/day
Number of subjects: 546

Group type: COMPARATOR
Intervention: Nimesulide only
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo LLLT with nimesulide 200 mg/day
Number of subjects: 546
Study: 17174854

Group type: EXPERIMENTAL
Intervention: Computer-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16311492

Group type: EXPERIMENTAL
Intervention: User-friendly low-literacy mailing with a $10 contingent incentive
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: User-friendly low-literacy mailing
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Standard mailing
Number of subjects: 968

Group type: COMPARATOR
Intervention: Standard mailing without incentive
Number of subjects: 968
Study: 11927713

Group type: COMPARATOR
Intervention: Tripedia at 2, 4, and 6 months of age (control group)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Tripedia at 2 and 4 months of age and Infanrix at 6 months of age
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Tripedia at 2 months and Infanrix at 4 and 6 months of age
Number of subjects: 449
Study: 10215997

Group type: EXPERIMENTAL
Intervention: Global brain ischaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double immunolabelling for poly(ADP‐ribose) and MAP2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PARP inhibitors
Number of subjects: 0
Study: 8585403

Group type: EXPERIMENTAL
Intervention: Nurse-initiated intervention
Number of subjects: 280
Study: 2354092

Group type: EXPERIMENTAL
Intervention: Morphine sulphate 500 micrograms
Number of subjects: 3

Group type: COMPARATOR
Intervention: Morphine-6-glucuronide (M6G) 500 micrograms
Number of subjects: 3

Group type: COMPARATOR
Intervention: Morphine sulphate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G)
Number of subjects: 3
Study: 831655

Group type: EXPERIMENTAL
Intervention: Multiphasic health testing
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Physical examinations by nurse practitioners supervised by physicians
Number of subjects: 6285

Group type: COMPARATOR
Intervention: Traditional physical examinations by physicians
Number of subjects: 6285
Study: 31359383

Group type: EXPERIMENTAL
Intervention: Genotype variation for SNP rs2153875
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Genotype variations of the Î²1 integrin activation domain
Number of subjects: 741
Study: 29131740

Group type: EXPERIMENTAL
Intervention: Prenatal yoga intervention (one-hour yoga class)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Attention control educational group (one-hour presentation on exercise, nutrition, and obesity in pregnancy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Prenatal yoga intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Attention control educational group
Number of subjects: 52